Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Kidney Int ; 93(2): 470-481, 2018 02.
Article En | MEDLINE | ID: mdl-28941939

Genetic analyses in atypical hemolytic uremic syndrome (aHUS) and C3-glomerulopathy (C3G) patients have provided an excellent understanding of the genetic component of the disease and informed genotype-phenotype correlations supporting an individualized approach to patient management and treatment. In this context, a correct categorization of the disease-associated gene variants is critical to avoid detrimental consequences for patients and their relatives. Here we describe a comprehensive procedure to measure levels and functional activity of complement regulator factor H (FH) encoded by CFH, the commonest genetic factor associated with aHUS and C3G, and present the results of the analysis of 28 uncharacterized, disease-associated, FH variants. Sixteen variants were not expressed in plasma and eight had significantly reduced functional activities that impact on complement regulation. In total, 24 of 28 CFH variants were unambiguously categorized as pathogenic and the nature of the pathogenicity fully documented for each. The data also reinforce the genotype-phenotype correlations that associate specific FH functional alterations with either aHUS or C3G and illustrate important drawbacks of the prediction algorithms dealing with variants located in FH functional regions. We also report that the novel aHUS-associated M823T variant is functionally impaired. This was unexpected and uncovered the important contribution of regions outside the N-terminal and C-terminal functional domains to FH regulatory activities on surfaces. Thus, our work significantly advances knowledge towards a complete functional understanding of the CFH genetic variability and highlights the importance of functional analysis of the disease-associated CFH variants.


Atypical Hemolytic Uremic Syndrome/genetics , Complement Activation/genetics , Genetic Variation , Glomerulonephritis/genetics , Adolescent , Adult , Atypical Hemolytic Uremic Syndrome/blood , Atypical Hemolytic Uremic Syndrome/diagnosis , Atypical Hemolytic Uremic Syndrome/immunology , Child , Child, Preschool , Complement C3/immunology , Complement Factor H/genetics , Complement Factor H/immunology , Complement Factor H/metabolism , Female , Genetic Association Studies , Genetic Predisposition to Disease , Glomerulonephritis/blood , Glomerulonephritis/diagnosis , Glomerulonephritis/immunology , Humans , Male , Middle Aged , Phenotype , Protein Domains , Registries , Risk Factors , Spain , Structure-Activity Relationship , Young Adult
2.
J Am Soc Nephrol ; 29(1): 240-249, 2018 01.
Article En | MEDLINE | ID: mdl-28993505

Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombotic microangiopathy caused by complement pathogenic variants, mainly affects the kidney microvasculature. A retrospective genetic analysis in our aHUS cohort (n=513) using multiple ligation probe amplification uncovered nine unrelated patients carrying a genetic abnormality in the complement factor H related 1 gene (CFHR1) that originates by recurrent gene conversion events between the CFH and CFHR1 genes. The novel CFHR1 mutants encode an FHR-1 protein with two amino acid substitutions, L290S and A296V, converting the FHR-1 C terminus into that of factor H (FH). Next-generation massive-parallel DNA sequencing (NGS) analysis did not detect these genetic abnormalities. In addition to the CFHR1 mutant, six patients carried the previously uncharacterized CFH-411T variant. In functional analyses, the mutant FHR-1 protein strongly competed the binding of FH to cell surfaces, impairing complement regulation, whereas the CFH-411T polymorphism lacked functional consequences. Carriers of the CFHR1 mutation presented with severe aHUS during adulthood; 57% of affected women in this cohort presented during the postpartum period. Analyses in patients and unaffected carriers showed that FH plasma levels determined by the nonmutated chromosome modulate disease penetrance. Crucially, in the activated endothelial (HMEC-1) cell assay, reduced FH plasma levels produced by the nonmutated chromosome correlated inversely with impairment of complement regulation, measured as C5b-9 deposition. Our data advance understanding of the genetic complexities underlying aHUS, illustrate the importance of performing functional analysis, and support the use of complementary assays to disclose genetic abnormalities not revealed by current NGS analysis.


Atypical Hemolytic Uremic Syndrome/genetics , Blood Proteins/genetics , Complement C3b Inactivator Proteins/genetics , Complement Factor H/genetics , Gene Conversion , Adult , Binding, Competitive , Cell Line , Complement Factor H/metabolism , Complement Membrane Attack Complex/metabolism , Female , High-Throughput Nucleotide Sequencing , Humans , Male , Middle Aged , Mutation , Pedigree , Penetrance , Retrospective Studies , Sequence Analysis, DNA/methods , Young Adult
3.
Immunobiology ; 222(2): 363-371, 2017 02.
Article En | MEDLINE | ID: mdl-27644115

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia characterized by complement-mediated intravascular hemolysis that is effectively treated with eculizumab. However, treatment responses are reported heterogeneous with some patients presenting residual hemolysis and requiring RBC transfusions. Recent reports have shown that both extravascular hemolysis and incomplete C5 blockade can explain these suboptimal hematological responses. Here we have tested our eculizumab-treated PNH patients (n=12) for signs of hemolysis and assessed complement biomarkers. Patients were also genotyped for complement receptor 1 (CR1, CD35) and C5 polymorphisms and evaluated for free eculizumab in plasma. We report that 10 patients (83%) present parameters suggesting persistent hemolysis, although they did not require additional transfusions. Seven of them (58%) become direct Coombs-test positive as a consequence of treatment, including all patients carrying the low-expression CR1-L allele. CH50 and sC5b-9 assays demonstrate that the persistent low-level hemolysis identified in our treated patients is not a consequence of incomplete C5 blockade, supporting that this hemolysis, as has been suggested previously, results from the extravascular removal of C3 opsonized PNH erythrocytes. We also show that continuous alternative pathway activation in eculizumab-treated individuals carrying the CR1-L allele results in abnormally decreased levels of C3 in plasma that could, potentially, increase their susceptibility to bacterial infections. Finally, we encourage a routine evaluation of free eculizumab levels and terminal pathway activity to personalize eculizumab administration.


Complement System Proteins/immunology , Hemoglobinuria, Paroxysmal/blood , Hemoglobinuria, Paroxysmal/immunology , Hemolysis/immunology , Antibodies, Monoclonal, Humanized/therapeutic use , Child , Child, Preschool , Complement Activation/drug effects , Complement Activation/immunology , Complement C3/immunology , Complement C5/immunology , Complement Inactivating Agents/therapeutic use , Cytotoxicity, Immunologic , Female , Genetic Predisposition to Disease , Genetic Variation , Genotype , Hemoglobinuria, Paroxysmal/diagnosis , Hemoglobinuria, Paroxysmal/drug therapy , Humans , Infant , Male , Receptors, Complement 3b/genetics , Receptors, Complement 3b/metabolism , Treatment Outcome
...